Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Orion Biotechnology Canada Ltd. announced that Sir Gregory Winter FRS has agreed to chair the Orion Biotechnology Scientific Advisory Board (SAB).
Retrophin, Inc. reported its second quarter 2019 financial results and provided a corporate update.
Gene therapy companies could be continued M&A targets for larger ones as more and more companies are looking to broaden their therapeutic focus with potential one-time therapies for various diseases.
Permira initiated the transaction after Cambrex flexed its own M&A muscle and acquired Avista and Halo.
Oxford Immunotec Global PLC, or the Company, a global, high-growth diagnostics company, announced second quarter 2019 financial results.
Funding will finance further development and IVD-CE marking of the company’s first molecular POC (Point of Care) platform, based on Pulse Controlled Amplification (PCA) technology
The owners of Cytena GmbH have agreed to sell all Cytena shares to CELLINK AB for a purchase price of 30.25M euros.
CELLINK AB has entered an agreement with the owners of cytena GmbH to acquire all cytena shares for a purchase price of 30.25M euros.
Loan reduced from US$30 million to US$11.5 million
Global Blood Therapeutics, Inc. announced that on August 1, 2019, the compensation committee of GBT’s board of directors granted 14 new employees options to purchase an aggregate of 26,200 shares of the company’s common stock with a per share exercise price of $54.25 and restricted stock units for an aggregate of 69,450 shares of the company’s common stock.